Today: The Aduro Biotech Inc. (ADRO) Rating Reiterate by Roth Capital

The Aduro Biotech Inc. (ADRO) Rating Reiterate by Roth Capital

Aduro Biotech Inc. (NASDAQ:ADRO)‘s stock had its “buy” rating reissued by research analysts at Roth Capital in a report issued on Thursday. They presently have a $20.00 target price on the stock, down from their prior target price of $22.00. Roth Capital’s price objective indicates a potential upside of 81.82% from the stock’s current price.

A number of other brokerages have also recently commented on ADRO. Canaccord Genuity reaffirmed a “buy” rating and set a $30.00 price target on shares of Aduro Biotech in a research report on Friday, August 5th. Zacks Investment Research cut Aduro Biotech from a “hold” rating to a “sell” rating in a research report on Monday, July 18th. Leerink Swann set a $14.00 price target on Aduro Biotech and gave the stock a “buy” rating in a research report on Monday, October 24th. Finally, FBR & Co reaffirmed an “outperform” rating and set a $20.00 price target (down previously from $22.00) on shares of Aduro Biotech in a research report on Wednesday, October 26th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. Aduro Biotech currently has a consensus rating of “Hold” and a consensus price target of $21.33.

Aduro Biotech (NASDAQ:ADRO) opened at 11.00 on Thursday. The firm’s 50-day moving average price is $12.92 and its 200 day moving average price is $12.97. The stock’s market cap is $712.29 million. Aduro Biotech has a 12-month low of $7.26 and a 12-month high of $34.95.

Aduro Biotech (NASDAQ:ADRO) last issued its quarterly earnings results on Wednesday, August 3rd. The company reported $0.03 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.21. Aduro Biotech had a negative return on equity of 9.23% and a negative net margin of 23.69%. The company earned $39 million during the quarter, compared to analysts’ expectations of $25.24 million. The business’s quarterly revenue was up 306.3% on a year-over-year basis. Analysts anticipate that Aduro Biotech will post ($1.39) EPS for the current year.

In other news, insider Jennifer Lew sold 6,360 shares of the business’s stock in a transaction dated Monday, September 19th. The stock was sold at an average price of $14.95, for a total value of $95,082.00. Following the completion of the transaction, the insider now owns 48,955 shares of the company’s stock, valued at approximately $731,877.25. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Stephen T. Isaacs sold 27,273 shares of the business’s stock in a transaction dated Monday, October 3rd. The shares were sold at an average price of $12.67, for a total value of $345,548.91. Following the completion of the transaction, the chief executive officer now directly owns 129,473 shares of the company’s stock, valued at approximately $1,640,422.91. The disclosure for this sale can be found here. 6.50% of the stock is owned by insiders.

Several institutional investors have recently modified their holdings of the stock. Emerald Acquisition Ltd. bought a new position in shares of Aduro Biotech during the second quarter valued at about $454,000. Palisade Capital Management LLC NJ boosted its position in Aduro Biotech by 6.5% in the second quarter. Palisade Capital Management LLC NJ now owns 50,478 shares of the company’s stock worth $571,000 after buying an additional 3,091 shares during the last quarter. California State Teachers Retirement System boosted its position in Aduro Biotech by 312.5% in the second quarter. California State Teachers Retirement System now owns 74,366 shares of the company’s stock worth $841,000 after buying an additional 56,340 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Aduro Biotech by 80.7% in the second quarter. Bank of New York Mellon Corp now owns 101,858 shares of the company’s stock worth $1,152,000 after buying an additional 45,482 shares during the last quarter. Finally, Alps Advisors Inc. boosted its position in Aduro Biotech by 27.7% in the second quarter. Alps Advisors Inc. now owns 90,766 shares of the company’s stock worth $1,027,000 after buying an additional 19,663 shares during the last quarter. 29.43% of the stock is owned by institutional investors and hedge funds.

About Aduro Biotech

Related posts

Leave a Comment